Selected article for: "coagulation test and significant difference"
Author: changzheng wang; Chengbin Li
Title: Preliminary study to identify severe from moderate cases of COVID-19 using NLR&RDW-SD combination parameter
  • Document date: 2020_4_14
    • ID: jecsj3xw_28
    Snippet: The Biochemical and coagulation test results of those 45 patients between Jan 23, 2020 and Feb 13, 2020 in our laboratory were presented in Table 3 . The biochemical and coagulation test samples were usually collected and tested once every 1-3 days. As the disease progressed, DBil, GLO, BUN, Cr, Cys C, CK, Mb, LDH and FBG in the severe group were significantly higher than that in the moderate group (P<0.05); meanwhile, ALB, Na + and Ca 2+ in the .....
    Document: The Biochemical and coagulation test results of those 45 patients between Jan 23, 2020 and Feb 13, 2020 in our laboratory were presented in Table 3 . The biochemical and coagulation test samples were usually collected and tested once every 1-3 days. As the disease progressed, DBil, GLO, BUN, Cr, Cys C, CK, Mb, LDH and FBG in the severe group were significantly higher than that in the moderate group (P<0.05); meanwhile, ALB, Na + and Ca 2+ in the severe group were significantly lower than that in the moderate group (P<0.05). There was no significant difference for all the coagulation test results between the two groups (P>0.05). The ROC curve was used to analyze the hematological parameters with significant differences between the two groups. The parameters with AUC <0.6 and no statistical significance (P> 0.05) with AUC = 0.5 were excluded. Next, we analyzed the diagnostic efficacy of other hematology parameters ( respectively. The combined parameters fitted by the LDA method were also used for the diagnostic efficacy analysis in the differentiation between the severe and the moderate groups.

    Search related documents:
    Co phrase search for related documents
    • AUC parameter and hematology parameter: 1, 2
    • AUC parameter and LDA method: 1, 2
    • AUC parameter and moderate group: 1, 2, 3
    • coagulation test and disease progress: 1
    • coagulation test and moderate group: 1
    • diagnostic efficacy and efficacy analysis: 1, 2, 3, 4
    • diagnostic efficacy and group significant difference: 1
    • diagnostic efficacy and moderate group: 1, 2
    • disease progress and group significant difference: 1, 2
    • disease progress and moderate group: 1, 2, 3, 4, 5
    • efficacy analysis and group significant difference: 1, 2, 3, 4, 5
    • efficacy analysis and moderate group: 1, 2
    • group significant difference and moderate group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • hematology parameter and LDA method: 1, 2
    • hematology parameter and moderate group: 1, 2
    • LDA method and moderate group: 1, 2